Antibody Drug Conjugates Market Overview:
Antibody Drug Conjugates Market are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. ADC’s are designed to eliminate cancer cells only without harming the normal cells. This is a major advantage of ADC’s as the unharmed healthy cells enable patients to recover faster. The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023.
Global Antibody Drug Conjugates Market Segmentation
The report segments the market based on drugs, technology, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyla. Based on mechanism of action, it is classified into CD30 antibodies and HER2 antibodies. Based on application, the market is categorized into breast cancer, lymphoma, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Increase in prevalence of cancer worldwide and unhealthy urban lifestyle and surge in consumption of tobacco and alcohol across geographies pose as major cancer risk factors. According to National Cancer Institute “the number of people living beyond cancer diagnosis is expected to reach approximately 19 million by 2024.” Increase in demand for cost-effective and quality cancer treatment is expected to drive the ADC’s market during the study period.
Global Antibody Drug Conjugates Market, by Geography, 2016 (% Share)
The report provides extensive competitive analysis and profiles of key market players, such as, include F. Hoffman-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Seattle Genetics Inc., Genentech Inc., Immunogen Inc., Immunomedics, Inc., Progenics Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals.
The other players in the value chain include Agensys, Inc., Concortis Biotherapeutics, Sanofi S.A., Celldex Therapeutics Inc., and Synthon Holding B.V.
Key Benefits :
- This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
- Market estimations are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based on geography assists to understand the regional market and the strategic business planning.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the antibody drug conjugates market.
Antibody Drug Conjugates Market Key Segments:
By Mechanism Of Action
- CD30 Antibodies
- HER2 Antibodies
- Breast Cancer
- North America
- The Netherlands
- Rest of Europe
- South Korea
- New Zealand
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA